Nordic Nanovector ASA (OTCPK:NRNVF)
$ 1.6383 0 (0%) Market Cap: 299.77 Mil Enterprise Value: 247.56 Mil PE Ratio: 0 PB Ratio: 2.40 GF Score: 25/100

Nordic Nanovector ASA -PARADIGME Update Transcript

Jul 06, 2022 / 06:30AM GMT
Jan Hendrik Egberts
Nordic Nanovector ASA - Independent Chairman of the Board

Good morning, ladies and gentlemen. My name is Jan Egberts, I'm the Chairman of Nordic Nanovector. Together with me here are Erik Skullerud, our CEO; Malene Brondberg, our CFO.

Unfortunately, it's a very sad day for all of us today. Openly, we had to announce last night the discontinuation of the PARADIGME clinical study for Betalutin. So obviously, in particular, a sad day but not just exclusively for the shareholders who put a lot of money in the company, but also for the employees who worked very hard and also have invested a lot of their personal money in our company.

And finally, and probably even more importantly, the patients who had expected a very positive new treatment for this very deadly disease. So unfortunately, we had to discontinue the clinical study. We're going to share some data with you. Unfortunately, we cannot share everything at this stage. And the reason for that is that the guidelines by the FDA, the Food and Drug Administration, which is the U.S. regulatory authority. They don't

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot